Dr. Colvin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Cox 5
Boston, MA 02114Phone+1 617-726-3812Fax+1 617-726-2894
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1999 - 2003
Brigham and Women's HospitalResidency, Internal Medicine, 1996 - 1999
Duke University School of MedicineClass of 1996
Certifications & Licensure
MA State Medical License 1998 - 2025- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 1 citationsBetibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open...Janet L Kwiatkowski, Mark C Walters, Suradej Hongeng, Evangelia Yannaki, Andreas E Kulozik
Lancet. 2024-11-30 - 8 citationsHematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.Christine N Duncan, Jacob R Bledsoe, Bartosz Grzywacz, Amy Beckman, Melissa Bonner
The New England Journal of Medicine. 2024-10-10 - 2 citationsDrug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.Dustin Whitney, Ilya Shestopalov, Maeva Fincker, Marc d'Anjou, Kelly Kral
Molecular Therapy. Methods & Clinical Development. 2023-12-14
Abstracts/Posters
- Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Either a _0 or IVS-I-110...Richard A. Colvin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Non-_0/_0 GenotypesRichard A. Colvin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Grant Support
- Signaling Through Chemokine Receptor CXCR3National Institute Of Allergy And Infectious Diseases2001–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
